 WALTHAM, Mass., Jan. 05, 2022 GLOBE NEWSWIRE -- Dyne Therapeutics, Inc. Nasdaq: DYN, a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. 